Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1821. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials

Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

1822. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting Full Text available with Trip Pro

Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting Roze S, Valentine W J, Evers T, Palmer A J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study considered the addition of acarbose to existing treatments in patients with Type 2 diabetes. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population comprised patients

2006 NHS Economic Evaluation Database.

1823. Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany

Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany Shearer A T, Bagust A, Liebl A, Schoeffski O, Goertz A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several treatments for patients with Type 2 diabetes were examined. For normal-weight and overweight patients, the combination of metformin (MET) and sulfonylurea (SUL) was compared with rosiglitazone (ROS) plus either SUL or MET. In obese patients, MET monotherapy was compared with ROS+MET, while MET+SUL was compared

2006 NHS Economic Evaluation Database.

1824. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain

Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain Shearer A T, Bagust A, Ampudia-Blasco F J, Alvarez B M, Escolano (...) E P, Paris G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of rosiglitazone (ROS) in combination with metformin (MET) for the treatment of Type 2 diabetes in obese or overweight patients. ROS was given at a dose of 4

2006 NHS Economic Evaluation Database.

1825. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data

Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus (...) pen device for the administration of insulin to patients with Type 2 diabetes mellitus. The comparator treatment was to take the insulin by injection (vial/syringe). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised adults with a diagnosis of Type 2 diabetes (International Classification of Diseases, 9th Revision, Clinical Modification, code 250.xx, excluding Type 1 subcodes) whose treatment was converted from

2006 NHS Economic Evaluation Database.

1826. Randomised controlled trial of near-patient testing in people with type 2 diabetes mellitus

Randomised controlled trial of near-patient testing in people with type 2 diabetes mellitus Randomised controlled trial of near-patient testing in people with type 2 diabetes mellitus Randomised controlled trial of near-patient testing in people with type 2 diabetes mellitus Khunti K, Stone M A, Burden A C, Turner D, Raymond N T, Burden M, Baker R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared two diagnostic procedures for testing glycated haemoglobin (HbA1c) in patients with Type 2 diabetes. The diagnostics tests compared were near-patient (rapid) testing and normal laboratory testing for HbA1c. Near-patient (rapid) testing is a technology offering on-site testing of patients for HbA1c (the equipment

2006 NHS Economic Evaluation Database.

1827. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension Palmer A J, Valentine W J, Tucker D M, Ray J A, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P (...) was not fully captured. Authors' conclusions The authors concluded that their model supported the early use of irbesartan in patients with microalbuminuria, hypertension and Type 2 diabetes. CRD commentary Interventions: Although the authors reported appropriate details of all the interventions under study, no explicit justification was given for using the control treatment as the comparator. In addition, the authors reported that, owing to the paucity of data, it was not possible to include angiotensin

2006 NHS Economic Evaluation Database.

1828. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland

Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland Health economic implications of irbesartan plus (...) conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland Palmer A J, Roze S, Valentine W J, Ray J A, Frei A, Burnier M, Hess B, Spinas G A, Brandle M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

2006 NHS Economic Evaluation Database.

1829. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes

Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes Palmer A J, Chen R, Valentine W J, Roze S, Bregman B, Mehin N, Gabriel S (...) Micral II semi-quantitative urine dipstick test strips. Treatment was the addition of irbesartan 300 mg/day to the patient's conventional therapy. Type of intervention Screening. Economic study type Cost-utility analysis. Study population The hypothetical study population comprised hypertensive patients with Type 2 diabetes with nephropathy. Setting The setting was primary care. The economic study was carried out in France. Dates to which data relate The effectiveness data related to studies

2006 NHS Economic Evaluation Database.

1830. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes

Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes Palmer A J, Dinneen S, Gavin J R, Gray A, Herman W H, Karter A J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the self-monitoring of blood glucose (SMBG) in patients with Type 2 diabetes. Type of intervention Diagnosis and treatment. Economic study type Cost-utility analysis. Study population The study population comprised three different cohorts of hypothetical patients with Type 2

2006 NHS Economic Evaluation Database.

1831. Telecare in a structured therapeutic education programme addressed to patients with type 1 diabetes and poor metabolic control

Telecare in a structured therapeutic education programme addressed to patients with type 1 diabetes and poor metabolic control Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

1832. The use of B-type natriuretic peptide in the management of patients with diabetes and acute dyspnoea

The use of B-type natriuretic peptide in the management of patients with diabetes and acute dyspnoea Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

1833. Cost-effectiveness of intermediate or long-acting insulin versus exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications

2005;143:559-69. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The Treat-to-Target trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91. Indexing Status Subject indexing (...) Cost-effectiveness of intermediate or long-acting insulin versus exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications Cost-effectiveness of intermediate or long-acting insulin versus exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications Cost-effectiveness of intermediate or long-acting insulin versus exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral

2006 NHS Economic Evaluation Database.

1834. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

1835. Adjunctive inhaled insulin before meals improved glycaemic control more than adjunctive metformin in type 2 diabetes mellitus Full Text available with Trip Pro

Adjunctive inhaled insulin before meals improved glycaemic control more than adjunctive metformin in type 2 diabetes mellitus Adjunctive inhaled insulin before meals improved glycaemic control more than adjunctive metformin in type 2 diabetes mellitus | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adjunctive inhaled insulin before meals improved glycaemic control more than adjunctive metformin in type 2 diabetes mellitus Article Text

2006 Evidence-Based Medicine

1836. Albumin to creatinine ratio in 2 random urine samples was an accurate screening test for albuminuria in diabetic pregnancies

Albumin to creatinine ratio in 2 random urine samples was an accurate screening test for albuminuria in diabetic pregnancies Albumin to creatinine ratio in 2 random urine samples was an accurate screening test for albuminuria in diabetic pregnancies | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Albumin to creatinine ratio in 2 random urine samples was an accurate screening test for albuminuria in diabetic pregnancies Article Text

2006 Evidence-Based Medicine

1837. Serum levels of activin A and inhibin A are not related to the increased susceptibility to pre-eclampsia in type I diabetic pregnancies (Abstract)

Serum levels of activin A and inhibin A are not related to the increased susceptibility to pre-eclampsia in type I diabetic pregnancies BACKGROUND: Activin A and inhibin A have been found to be elevated in women without diabetes subsequently developing pre-eclampsia. The aim was to investigate whether activin A and inhibin A in serum were elevated in type I diabetic women after developing pre-eclampsia and, if so, were they clinically useful as predictors of pre-eclampsia. METHODS (...) : In a prospective study, maternal serum was analyzed for activin A and inhibin A in 115 women with type 1 diabetes at 10, 14, 22, 28, and 33 weeks of gestation. RESULTS: Fourteen women (12%) developed pre-eclampsia (26-37 weeks of gestation) and 101 did not. The two groups were comparable regarding age, body mass index, and diabetes duration. There was no difference between serum concentrations of activin A and inhibin A in women developing pre-eclampsia and women who did not at any gestational period

2006 EvidenceUpdates

1838. Resistance Training and Type 2 Diabetes: Considerations for implementation at the population level. Full Text available with Trip Pro

Resistance Training and Type 2 Diabetes: Considerations for implementation at the population level. Resistance training and type 2 diabetes: Considerations for implementation at the population level. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation (...) manager Format Create File 1 selected item: 16873809 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2006 Aug;29(8):1933-41. Resistance training and type 2 diabetes: Considerations for implementation at the population level. 1 , . 1 Faculty of Physical Education, University of Alberta, Edmonton, Canada. PMID: 16873809 DOI: [Indexed

2006 EvidenceUpdates

1839. Duration of lactation and incidence of type 2 diabetes. Full Text available with Trip Pro

Duration of lactation and incidence of type 2 diabetes. Lactation is associated with improved glucose and insulin homeostasis, independent of weight change.To evaluate the association between lactation history and incidence of type 2 diabetes.Prospective observational cohort study of 83,585 parous women in the Nurses' Health Study (NHS) and retrospective observational cohort study of 73,418 parous women in the Nurses' Health Study II (NHS II).Incident cases of type 2 diabetes mellitus.In (...) the NHS, 5145 cases of type 2 diabetes were diagnosed during 1,239,709 person-years of follow-up between 1986 and 2002, and in the NHS II, 1132 cases were diagnosed during 778,876 person-years of follow-up between 1989 and 2001. Among parous women, increasing duration of lactation was associated with a reduced risk of type 2 diabetes. For each additional year of lactation, women with a birth in the prior 15 years had a decrease in the risk of diabetes of 15% (95% confidence interval, 1%-27%) among NHS

2005 JAMA

1840. Role of the mitochondrial DNA 16184-16193 poly-C tract in type 2 diabetes. (Abstract)

Role of the mitochondrial DNA 16184-16193 poly-C tract in type 2 diabetes. Recent evidence suggests that polymorphic genetic variation in the non-coding region of mitochondrial DNA (the 16184-16193 polycytosine [poly-C] tract) contributes to the cause of type 2 diabetes, but previous studies only just reached significance. We aimed to investigate this association. We compared patients with type 2 diabetes (n=992) with two independent control groups (n=536, n=1029) from the UK, and saw (...) no difference in the frequency of the 16184-16193 poly-C tract. This finding was confirmed by a meta-analysis of European studies of 1455 patients and 3132 controls (odds ratio 1.16, 95% CI 0.94-1.44). Genetic variation of the 16184-16193 poly-C tract is unlikely to have a major role in the cause of type 2 diabetes.

2005 Lancet